Cabaletta Bio Inc (CABA)
12.34
-0.28
(-2.22%)
USD |
NASDAQ |
May 17, 16:00
12.67
+0.33
(+2.67%)
After-Hours: 20:00
Cabaletta Bio Cash from Investing (TTM): -47.88M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -47.88M |
| December 31, 2023 | -22.45M |
| September 30, 2023 | -23.90M |
| June 30, 2023 | 0.07M |
| March 31, 2023 | 47.31M |
| December 31, 2022 | -27.22M |
| September 30, 2022 | -26.05M |
| June 30, 2022 | -48.19M |
| March 31, 2022 | -46.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 5.999M |
| September 30, 2021 | 7.041M |
| June 30, 2021 | 6.742M |
| March 31, 2021 | -5.402M |
| December 31, 2020 | -7.981M |
| September 30, 2020 | -10.14M |
| June 30, 2020 | -11.66M |
| March 31, 2020 | -0.739M |
| December 31, 2019 | -0.693M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-48.19M
Minimum
Jun 2022
47.31M
Maximum
Mar 2023
-11.75M
Average
-9.063M
Median
Cash from Investing (TTM) Benchmarks
| Editas Medicine Inc | -31.74M |
| ACADIA Pharmaceuticals Inc | -174.56M |
| Alnylam Pharmaceuticals Inc | -327.75M |
| Regeneron Pharmaceuticals Inc | -4.636B |
| Vertex Pharmaceuticals Inc | -3.444B |